Sienna Durbin

846 total citations
28 papers, 450 citations indexed

About

Sienna Durbin is a scholar working on Oncology, Economics and Econometrics and Epidemiology. According to data from OpenAlex, Sienna Durbin has authored 28 papers receiving a total of 450 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Economics and Econometrics and 6 papers in Epidemiology. Recurrent topics in Sienna Durbin's work include Cancer Immunotherapy and Biomarkers (13 papers), Economic and Financial Impacts of Cancer (11 papers) and Health Systems, Economic Evaluations, Quality of Life (8 papers). Sienna Durbin is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Economic and Financial Impacts of Cancer (11 papers) and Health Systems, Economic Evaluations, Quality of Life (8 papers). Sienna Durbin collaborates with scholars based in United States, Thailand and China. Sienna Durbin's co-authors include Hannah R. Abrams, Shawn F. Johnson, Rahul Nayak, Jeffrey Peppercorn, Cher X. Huang, Greg J. Zahner, Zachary T. Schafer, Sarah E. Chapman, Connor Wathen and Justin Diener and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Cancer.

In The Last Decade

Sienna Durbin

23 papers receiving 445 citations

Peers

Sienna Durbin

ONCOL

EPIDE

Gabriel Tremblay United States

Bakarou Kamaté Mali

Shanthi Sivendran United States

Bianca Devitt Australia

Andrew Ip United States

Melvin Chin Australia

Colleen Lewis United States

Jessica Star United States

Jessie Ehrisman United States

Susanna Hilda Hutajulu Indonesia

Gabriel Tremblay United States

Sienna Durbin

107 ×0.6

ONCOL

84 ×0.7

56 ×0.6

25 ×0.4

27 ×0.4

EPIDE

Citations per year, relative to Sienna Durbin Sienna Durbin (= 1×) peers Gabriel Tremblay

Countries citing papers authored by Sienna Durbin

Since Specialization

Citations

This map shows the geographic impact of Sienna Durbin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sienna Durbin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sienna Durbin more than expected).

Fields of papers citing papers by Sienna Durbin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sienna Durbin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sienna Durbin. The network helps show where Sienna Durbin may publish in the future.

Co-authorship network of co-authors of Sienna Durbin

This figure shows the co-authorship network connecting the top 25 collaborators of Sienna Durbin. A scholar is included among the top collaborators of Sienna Durbin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sienna Durbin. Sienna Durbin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Durbin, Sienna, Chia‐Yun Wu, Jaclyn LoPiccolo, et al.. (2025). Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy. JAMA Network Open. 8(3). e252668–e252668. 10 indexed citations

Durbin, Sienna, Andrea Pelletier, Laura A. Petrillo, et al.. (2024). Change in financial toxicity during early-phase cancer clinical trial (EP-CT) participation.. Journal of Clinical Oncology. 42(16_suppl). 11119–11119. 1 indexed citations

Pelletier, Andrea, Sienna Durbin, Laura A. Petrillo, et al.. (2024). Associations of symptom burden with patient-reported outcomes (PROs) and clinical outcomes among early-phase cancer clinical trial (EP-CT) participants.. Journal of Clinical Oncology. 42(16_suppl). 11101–11101.

Durbin, Sienna, Andrea Pelletier, Laura A. Petrillo, et al.. (2024). Financial toxicity in early‐phase cancer clinical trial participants. Cancer. 131(1). e35586–e35586. 1 indexed citations

Jain, Sandeep, Mark F. Lythgoe, Sienna Durbin, et al.. (2024). Toxicity surveillance in FDA pivotal registration trials for immune checkpoint inhibitors: Are we missing the mark?. JCO Oncology Practice. 20(10_suppl). 215–215. 1 indexed citations

Badran, Yousef R., Fangwen Zou, Sienna Durbin, et al.. (2023). Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis. Journal for ImmunoTherapy of Cancer. 11(6). e007195–e007195. 17 indexed citations

Durbin, Sienna, et al.. (2023). Frequency of delayed immune-related adverse events (irAEs) in hospitalized patients treated with immune checkpoint inhibitors (ICIs).. Journal of Clinical Oncology. 41(16_suppl). 2652–2652.

Durbin, Sienna, Andrea Pelletier, Laura A. Petrillo, et al.. (2023). Patient-reported hope, prognostic understanding, quality of life, symptom burden, coping mechanisms, and financial wellbeing in early phase clinical trial participants.. Journal of Clinical Oncology. 41(16_suppl). 12109–12109.

Durbin, Sienna, Andrea Pelletier, Laura A. Petrillo, et al.. (2023). Financial toxicity, quality of life, symptom burden, and access to resources in early-phase clinical trial (EP-CT) participants.. Journal of Clinical Oncology. 41(16_suppl). 6623–6623.

10.

Pelletier, Andrea, Sienna Durbin, Dejan Juric, et al.. (2022). Patient-reported hope, quality of life, symptom burden, coping, and financial toxicity in early-phase clinical trial participants.. Journal of Clinical Oncology. 40(28_suppl). 275–275.

11.

Durbin, Sienna, Rachel Jimenez, Tristan Martin, et al.. (2021). Time burden and logistical intensity of early-phase clinical trials (EP-CTs).. Journal of Clinical Oncology. 39(28_suppl). 84–84. 1 indexed citations

12.

Abrams, Hannah R., Sienna Durbin, Cher X. Huang, et al.. (2021). Financial toxicity in cancer care: origins, impact, and solutions. Translational Behavioral Medicine. 11(11). 2043–2054. 121 indexed citations

13.

Thompson, Leah L., Ethan Katznelson, Donna Leet, et al.. (2020). Impact of systemic corticosteroids on survival outcomes in immune checkpoint inhibitor–induced gastroenterocolitis. European Journal of Cancer. 142. 143–146. 7 indexed citations

14.

Petrillo, Laura A., Areej El‐Jawahri, Ryan David Nipp, et al.. (2020). Performance status and end‐of‐life care among adults with non–small cell lung cancer receiving immune checkpoint inhibitors. Cancer. 126(10). 2288–2295. 48 indexed citations

15.

Turbett, Sarah E., Melis N. Anahtar, Anand S. Dighe, et al.. (2020). Evaluation of Three Commercial SARS-CoV-2 Serologic Assays and Their Performance in Two-Test Algorithms. Journal of Clinical Microbiology. 59(1). 40 indexed citations

16.

Durbin, Sienna, Leyre Zubiri, Andrzej Niemierko, et al.. (2020). Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. The Oncologist. 26(1). 49–55. 13 indexed citations

17.

Durbin, Sienna, Meghan J. Mooradian, Florian J. Fintelmann, et al.. (2020). Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. Journal for ImmunoTherapy of Cancer. 8(2). e001329–e001329. 16 indexed citations

18.

Durbin, Sienna, Leyre Zubiri, Andrzej Niemierko, et al.. (2019). Clinical outcomes of patients with stage IV cancer receiving immune checkpoint inhibitors in the inpatient setting.. Journal of Clinical Oncology. 37(15_suppl). 6634–6634. 2 indexed citations

19.

Mason, Joshua A., et al.. (2016). Oncogenic Ras differentially regulates metabolism and anoikis in extracellular matrix-detached cells. Cell Death and Differentiation. 23(8). 1271–1282. 53 indexed citations

20.

Durbin, Sienna, Victoria R. Zellmer, Sarah E. Chapman, et al.. (2013). Antioxidant Enzymes Mediate Survival of Breast Cancer Cells Deprived of Extracellular Matrix. Cancer Research. 73(12). 3704–3715. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact